Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition

Authors

Michael Vacher
Tenielle Porter, Edith Cowan UniversityFollow
Victor L. Villemagne
Lidija Milicic, Edith Cowan UniversityFollow
Madeline Peretti, Edith Cowan UniversityFollow
Christopher C. Fowler
Ralph Martins, Edith Cowan UniversityFollow
Stephanie Rainey-Smith, Edith Cowan UniversityFollow
David Ames
Colin L. Masters
Christopher C. Rowe
James D. Doecke
Simon M. Laws, Edith Cowan UniversityFollow

Document Type

Journal Article

Publication Title

Scientific Reports

Publisher

Springer Nature

School

School of Medical and Health Sciences

RAS ID

30230

Comments

Vacher, M., Porter, T., Villemagne, V. L., Milicic, L., Peretti, M., Fowler, C., ... Laws, S. M. (2019). Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition. Scientific Reports, 9, Article 17069. Available here

Abstract

The accumulation of brain amyloid β (Aβ) is one of the main pathological hallmarks of Alzheimer’s disease (AD). However, the role of brain amyloid deposition in the development of AD and the genetic variants associated with this process remain unclear. In this study, we sought to identify associations between Aβ deposition and an a priori evidence based set of 1610 genetic markers, genotyped from 505 unrelated individuals (258 Aβ+ and 247 Aβ−) enrolled in the Australian Imaging, Biomarker & Lifestyle (AIBL) study. We found statistically significant associations for 6 markers located within intronic regions of 6 genes, including AC103796.1-BDNF, PPP3R1, NGFR, KL, ABCA7 & CALHM1. Although functional studies are required to elucidate the role of these genes in the accumulation of Aβ and their potential implication in AD pathophysiology, our findings are consistent with results obtained in previous GWAS efforts.

DOI

10.1038/s41598-019-53604-5

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.